Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

NIH to Test Maraviroc-Based Drug Regimens for HIV Prevention

Published: Thursday, July 19, 2012
Last Updated: Thursday, July 19, 2012
Bookmark and Share
Safety, tolerability study to enroll MSM in the United States and Puerto Rico.

Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection.

The eventual goal is to see if the drug regimens can reduce the risk of infection.

The trial involves a strategy known as pre-exposure prophylaxis, or PrEP, in which HIV-uninfected individuals who are at risk for contracting the virus take one or two HIV drugs routinely in an effort to prevent infection.

Called Novel Exploration of Therapeutics for PrEP, or NEXT-PrEP, the two-year study is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

"The NEXT-PrEP study will examine whether maraviroc-based PrEP is safe and well-tolerated. It is a necessary first step before we can test the effectiveness of maraviroc-based PrEP, and in the future, potentially expand the selection of drugs that may be used in this emerging HIV prevention strategy," said NIAID Director Anthony S. Fauci, M.D.

Led by principal investigator Roy M. Gulick, M.D., M.P.H., chief of the Division of Infectious Diseases and professor of medicine at Weill Cornell Medical College of Cornell University, the study team will enroll 400 HIV-uninfected men who have sex with men (MSM) ages 18 and older in 12 cities in the United States and Puerto Rico.

The volunteers will be assigned at random to take one of the following four PrEP study regimens daily for 48 weeks:
• Maraviroc (300 milligrams)
• Maraviroc (300 milligrams) plus emtricitabine (200 milligrams)
• Maraviroc (300 milligrams) plus tenofovir disoproxil fumarate (300 milligrams)
• Emtricitabine (200 milligrams) plus tenofovir disoproxil fumarate (300 milligrams)

Placebo pills will be added to the regimens as needed so that neither the participants nor the study team will know who is taking which regimen.

The investigators will observe whether the volunteers experience any serious side effects and assess whether they continue taking their PrEP regimens as recommended.

If the study drugs appear to compromise a participant's health, he will be directed to stop taking them.

All participants will regularly be tested for HIV infection and receive condoms and counseling on how to reduce their risk of becoming infected with the virus.

The NIH-funded HIV Prevention Trials Network (HPTN), in collaboration with the AIDS Clinical Trials Group (ACTG), is conducting the NEXT-PrEP study, also called HPTN 069/ACTG 5305. Gilead Sciences Inc. of Foster City, Calif., and ViiV Healthcare of Brentford, England, are donating the study drugs.

This trial builds on the results of the NIAID-sponsored iPrEx study (, which found in 2010 that the daily PrEP regimen of oral tenofovir plus emtricitabine (brand name Truvada) reduced the risk of HIV infection in MSM by 43.8 percent.

The NEXT-PrEP study leaders chose to examine PrEP regimens containing maraviroc (brand name Selzentry) for several reasons. All other PrEP regimens tested to date involve tenofovir alone or in combination with emtricitabine.

Concerns about potential toxicity and the development of drug resistance suggested to the scientists that a wider array of antiretroviral drugs with optimal properties for HIV prevention should be explored.

Maraviroc, manufactured by ViiV Healthcare, was approved by the U.S. Food and Drug Administration in 2007 to treat HIV/AIDS and has continued to demonstrate safety and effectiveness in HIV-infected individuals.

The drug prevents HIV from entering cells, unlike tenofovir and emtricitabine, which interfere with HIV replication after the virus has infected a cell.

Maraviroc rarely engenders resistance and although approved in the U.S. for use in patients beginning HIV treatment, it is not commonly used this way in a clinical setting.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Thursday, July 02, 2015
Drugs that Activate Brain Stem Cells May Reverse Multiple Sclerosis
NIH-funded study identifies over-the-counter compounds that may replace damaged cells.
Tuesday, April 21, 2015
Allergy Drug Inhibits Hepatitis C in Mice
NIH study suggests alternative drug to treat virus.
Friday, April 10, 2015
Barrier-Breaking Drug May Lead to Spinal Cord Injury Treatments
NIH-funded scientists take first step towards developing promising new drug.
Thursday, December 04, 2014
Two Drugs are No More Effective Than One to Treat Common Kidney Disease
NIH study finds limited kidney benefit from more rigorous blood pressure treatment.
Saturday, November 29, 2014
New Drug for Common Liver Disease Improves Liver Health
An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the NIH.
Monday, November 10, 2014
First Drug Candidate from NIH Program Acquired by Baxter
Potential treatment targets sickle cell disease.
Tuesday, July 15, 2014
Drug Does Not Improve Set of Cardiovascular Outcomes for Diastolic Heart Failure
NIH-supported study finds drug does appear to reduce hospitalizations for diastolic heart failure.
Tuesday, April 15, 2014
NIH, Industry and Non-Profits Join Forces to Speed Validation of Disease Targets
Goal is to develop new treatments earlier, beginning with Alzheimer's, type 2 diabetes, and autoimmune disorders.
Tuesday, February 11, 2014
Tobacco, Drug Use in Pregnancy Can Double Risk of Stillbirth
NIH network study documents elevated risk associated with marijuana, other substances.
Tuesday, December 24, 2013
Exploring Structure-Activity Data Using the Landscape Paradigm
Structure-activity relationships represent a core aspect of medicinal chemistry.
Friday, November 08, 2013
NIH Launches Trial for Rare Degenerative Muscle Disease Treatment
Clinical trial to evaluate the drug candidate DEX-M74 as a treatment for HIBM.
Tuesday, September 25, 2012
NIH Researchers Implicate Unique Cell Type in Multiple Sclerosis
Study reveals new effects of the investigational MS drug daclizumab.
Friday, August 03, 2012
Neighbors Help Cancer Cells Resist Treatment
New study reveals that surrounding cells help tumors develop resistance to drugs.
Wednesday, July 25, 2012
NIH Funds Development of Tissue Chips to Help Predict Drug Safety
DARPA and FDA to collaborate on therapeutic development initiative.
Wednesday, July 25, 2012
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos